The 81st Annual Meeting of the Japanese Cancer AssociationThe 81st Annual Meeting of the Japanese Cancer Association

Category

1 Chemical carcinogenesis and radiation carcinogenesis

1-1 Activation and metabolism of carcinogens
1-2 Detection and assessment of carcinogens
1-3 DNA damage
1-4 Process of carcinogenesis
1-5 Nitric oxide/reactive oxygen
1-6 Genotoxins and nongenotoxins
1-7 Experimental cell culture systems
1-8 Radiation and electromagnetic wave carcinogenesis
1-9 Others

2 Experimental animal models and genetically-engineered animals

2-1 Gene-manipulated animal models
2-2 Animal model for carcinogenesis
2-3 Patient-derived experimental model
2-4 Others

3 Virus, infection, inflammation and cancer

3-1 EBV
3-2 HPV
3-3 HBV
3-4 HCV
3-5 HTLV-1
3-6 HHV-8
3-7 H.pylori
3-8 Other viruses/bacteria
3-9 Intestinal bacteria/microbiome
3-10 Inflammation and cancer

4 Oncogenes and tumor-suppressor genes

4-1 ras family genes
4-2 p53-related genes
4-3 Rb/p16-related genes
4-4 Wnt signaling-related genes
4-5 Chromosomal translocation-related genes
4-6 Other oncogenes/tumor-suppressor genes
4-7 Novel oncogenes/tumor-suppressor genes

5 Signal transduction and gene expression

5-1 5-1. Proliferation/differentiation
5-2 Signal transduction
5-3 Transcriptional regulation
5-4 Translational regulation
5-5 RNA engineering
5-6 ncRNA・microRNA
5-7 Single cell analysis
5-7 Others

6 DNA replication/cell cycle/genomic instability

6-1 Cell cycle/checkpoint
6-2 DNA replication
6-3 DNA repair
6-4 Genetic instability

7 Cancer genome/genetics

7-1 Genomic analysis
7-2 Clonal evolution
7-3 Genomic medicine/precision medicine
7-4 NGS
7-5 Genome editing
7-6 Chromosomal translocation/gene rearrangement
7-7 Copy number analysis
7-8 Familial tumor and target genes
7-9 Carcinogenic sensitivity-related genes (SNPs)
7-10 Others

8 Cell death/immortalization

8-1 Cell death
8-2 Telomere/senescence/immnortalization
8-3 Others

9 Epigenetics

9-1 DNA methylation
9-2 Histone modification
9-3 Chromatin structure
9-4 Others

10 Invasion and metastasis

10-1 Cell adhesion/invasion
10-2 Extracellular matrices and proteases
10-3 Metastasis-associated genes
10-4 Angiogenesis
10-5 Diagnosis of metastasis
10-6 Metastasis inhibition
10-7 Metastasis models
10-8 EMT (epithelial-mesenchymal transition)
10-9 Others

11 Characteristics of cancer cells

11-1 Cancer stem cellｓ
11-2 Cell differentiation
11-3 Tumor heterogeneity
11-4 Cell-to-cell interaction/adhesion molecules
11-5 Cell lines
11-6 Organoid
11-7 Carbohydrate chains and glycosyltransferases
11-8 Extracellular vesicles/Exosome
11-9 Metabolism / Metabolome
11-10 Others

12 Cancer immunity

12-1 Innate immunity
12-2 Dendritic cells/antigen-presenting cells
12-3 Tumor antigens
12-4 Antitumor effector cells and their induction
12-5 Immune checkpoint inhibitors
12-6 Cell therapy
12-7 Antibody therapy
12-8 Other immunotherapies
12-9 Others

13 Growth factors/cytokines/hormones

13-1 Growth- and differentiation-regulating factors
13-2 Growth factor receptors
13-3 Hormones
13-4 Cytokines
13-5 TGF-b/Smad

14 Cancer basic, diagnosis and treatment

14-1 Gastric cancer
14-2 Esophageal cancer
14-3 Colorectal cancer
14-4 GIST
14-5 Liver cancer
14-6 Carcinoma of the biliary tract
14-7 Pancreatic cancer
14-8 Lung cancer
14-9 Breast cancer
14-10 Uterine cancer
14-11 Ovarian cancer
14-12 hematopoietic malignancy
14-13 Renal cell cancer
14-14 Bladder cancer
14-15 Prostatic cancer
14-16 Testicular cancer
14-17 Brain tumor
14-18 Primary bone tumor
14-19 Soft tissue sarcoma
14-20 Head and neck cancer
14-21 Endocrine cancer
14-22 Skin cancer
14-23 Childhood cancer/AYA
14-24 Other organs

15 Diagnosis

15-1 Pathological diagnosis
15-2 Pathological analysis
15-3 Diagnostic imaging/cancer imaging
15-4 Diagnosis by tumor markers and biomarkers
15-5 Genomic diagnostics/Panel sequencing
15-6 Diagnosis by expression analysis (mRNA, protein)
15-7 Novel diagnostic technology
15-8 Liquid biopsy
15-9 Artificial intelligence based diagnostics
15-10 Others

16 Molecular-targeting therapy

16-1 Signal transduction inhibitors/kinase inhibitors
16-2 Angiogenesis inhibitors/antimetastatic drugs
16-3 Cell cycle inhibitors (CDK inhibitors etc.)
16-4 Epigenetic drugs
16-5 Proteolysis (proteasome inhibitors/PROTAC)
16-6 Engineered antibodies (ADC etc.)
16-7 Others

17 Chemotherapy and endocrine therapy

17-1 Natural anticancer compounds
17-2 Synthetic anticancer compounds
17-3 DNA-damaging drug (Platinum compounds/Topoisomerase inhibitors etc.)
17-4 Antimetabolites
17-5 Antimicrotubular drugs (taxane/alkaloids etc.)
17-6 Anticancer drug resistance
17-7 Anticancer drug and cell death
17-8 Endocrine therapy
17-9 Differentiation-inducing therapy
17-10 Drug delivery system
17-11 Combinational therapy/adjuvant therapy
17-12 Others

18 Evaluation and prediction of pharmacological effects

18-1 Drug sensitivity/drug resistance-relating factors/gene expression analysis
18-2 Pharmacokinetics/pharmacodynamics (PK/PD)
18-3 Pharmacogenomics/toxicogenomics (SNPs, transcriptome, proteome)
18-4 Sensitivity test
18-5 Clinical trial
18-6 Translational research
18-7 Biobank

19 Radiation therapy

19-1 Radiation and particle ray therapy
19-2 Radiation hazard/protection
19-3 Radiosensitivity
19-4 Efficacy enhancement
19-5 Hyperthermia
19-6 Others

20 Cell therapy and regeneration medicine

20-1 Stem cells
20-2 Regenerative medicine
20-3 Cell therapy of allograft
20-4 Others

21 Gene therapy

21-1 Generation and modification of vectors
21-2 Immunogenetic therapy
21-3 Oncogene/tumor-suppressor gene therapy
21-4 Suicide gene therapy
21-5 Nucleic acid therapeutics (including DDS)
21-6 Others

22 Medical care of progressive cancer

22-1 Psychooncology
22-2 Palliative treatment and care
22-3 Others

23 Cancer prevention/chemoprevention

23-1 Mechanism of cacinogenesis inhibition
23-2 Synthetic compounds
23-3 Natural products
23-4 Dietary/alimentary factors
23-5 Others

24 Epidemiology

24-1 Environmental factors (life habits etc.)/infectious exposure
24-2 Cancer prone syndromes/molecular epidemiology
24-3 Cohort study
24-4 Descriptive epidemiology/cancer registration
24-5 Cancer screening
24-6 Others

25 Information/informatics

25-1 Bioinfomatics
25-2 Big Data/Real World Data analysis
25-3 Management and analysis of cancer patients' data
25-4 Mathmatical modeling and simulation
25-5 Others

26 Cancer and society

26-1 Informed consent
26-2 Bioethics
26-3 Social movement against cancer
26-4 Smoking and drinking alcohol
26-5 Others